Cargando…
The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A
BACKGROUND: Risk factors for the development of inhibitors in previously untreated patients (PUPs) have been reported; this is not the case in previously treated patients (PTPs) owing to fewer studies. Risk factors may differ for the development of PTP versus PUP inhibitors. We aimed to identify ris...
Autores principales: | Kim, Ju Young, You, Chur Woo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779946/ https://www.ncbi.nlm.nih.gov/pubmed/31730688 http://dx.doi.org/10.5045/br.2019.54.3.204 |
Ejemplares similares
-
Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019) -
Clinical analysis of hospitalized patients with hemophilia A: single-hemophilia treatment center experience in Korea over 10 years
por: Kim, Ju Young, et al.
Publicado: (2021) -
Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services
por: Oudat, Raida, et al.
Publicado: (2020) -
FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
por: Hart, Daniel P.
Publicado: (2020) -
Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)